5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Glaxosmithkline Pharmaceuticals Ltd.

•
gsk-india.comBSE: 500660NSE: GLAXO
Market Cap₹ 48,064 Cr.
Current Price
High / Low₹ 3,121 / 2,088
Stock P/E45.0
Book Value₹ 149
Price to Book16.94
Dividend Yield2.01 %
ROCE66.8 %
ROE48.8 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 29.2% CAGR over last 5 years
  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 60.3%
  • Company has a good return on equity (ROE) track record: 3 Years ROE 43.9%
  • Company has consistently been profitable over the last 5 years
  • Operating margins have improved to 31.0% from 25.4%

CONS

  • Stock is trading at 16.9x its book value
  • Recurring exceptional / one-off items are inflating headline profit
  • Company has delivered a poor sales growth of 5.5% over past five years
  • Growth is decelerating - 3Y profit CAGR (19.5%) trails the 5Y trend (29.2%)
  • Expensive relative to growth - PEG of 2.3

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTYLARGEMIDCAP250NIFTYMIDCAP150NIFTY MIDCAP 150NIFTY TOTAL MKTNIFTY 500
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.GLAXO2837.2045.0048063.882.01237.1815.69938.4416.5566.7931.49
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
7629578059308151,0119499748059801,041995938
618668587673584689658641554644670644660
Operating Profit144289218257231322292333251336371351279
OPM %18.89%30.25%27.08%27.67%28.30%31.83%30.75%34.20%31.20%34.26%35.66%35.26%29.70%
5428-13532363935414436503644
Interest0001000101111
Depreciation16181718161719151617201316
Profit before Tax18129965271249344308359279354400373322
Tax %26.93%27.29%30.12%28.14%26.89%26.56%25.39%26.69%26.51%27.26%26.08%25.53%26.44%
Net Profit0000182252230263205257296278237
7.8112.842.7011.4810.7614.6713.5715.5212.1015.0717.4516.4014.00

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
2,9082,8713,1283,2242,9263,2783,2523,4543,7493,8223,955
2,4892,3662,5272,5672,3272,5162,4472,5452,5722,5122,618
Operating Profit4195066016575987628049091,1771,3091,337
OPM %14.41%17.61%19.21%20.38%20.45%23.24%24.73%26.31%31.40%34.26%33.80%
11972131-262-6287100-21151166166
Interest00164222133
Depreciation2638498379686670676667
Profit before Tax5115406833064547798368161,2601,4061,449
Tax %34.11%35.05%34.76%69.52%36.72%51.12%27.35%27.72%26.38%26.32%26.31%
Net Profit337351445932873816085909281,0361,068
EPS39.7620.7026.295.5021.14100.0436.0534.8354.7661.15—
Dividend Payout %75.45%84.53%76.07%727.03%141.90%89.96%88.77%91.89%98.62%93.21%—

COMPOUNDED SALES GROWTH

10 Years:
3%
5 Years:
5%
3 Years:
6%

COMPOUNDED PROFIT GROWTH

10 Years:
11%
5 Years:
24%
3 Years:
19%

STOCK PRICE CAGR

10 Years:
7%
5 Years:
13%
3 Years:
25%
1 Year:
-1%

RETURN ON EQUITY

10 Years:
25%
5 Years:
36%
3 Years:
44%
Last Year:
49%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2018

Sep 11

1:1

Bonus issue Inter alia, 1. Mr. Marc Jones, Non-Executive Director and Mr. Rajeshwar R. Bajaaj, Independent Director have ceased to be a Directors of the Company from close of the business hours on 24th July 2018. 2. Bonus Issue The Board considered, approved and recommended a bonus issue of one equity share for every equity share held as on a record date to be determined. The bonus issue of equity shares will be subject to approval by the shareholders, and any other applicable statutory and regulatory approvals. The Bonus shares once allotted shall rank pari-passu in all respects and carry the same rights as the existing Equity Shares and shall be entitled to participate in full in any dividend and other corporate action, recommended and declared after the new equity shares are allotted

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital8585169169169169169169169169
1,9221,9731,9701,6511,3092,4941,5741,6171,7972,114
43229221047217
Trade Payables279506406357466579428625708570
4,2975,0735,2568161,0451,2681,0189921,2901,319
Total Liabilities6,5887,6397,8043,0233,0124,5203,1933,4103,9674,190
253323430757386329329320283280
Capital Work in Progress5739231,003120133120141433
000003665188131,1181,392
426500486483547535460525482458
0000000222293273
Cash & Bank9001,2961,1711,0831,1582,4851,1561,0631,4041,391
4,4364,5964,714580908775710452374364
Total Assets6,5887,6397,8043,0233,0124,5203,1933,4103,9674,190

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
3926756187047439597567211,290903
Cash from Investing301-104-153-57418-4068089-46397
Cash from Financing-511-307-358-428-696-524-1,543-561-769-737
2462-1026300-119-25129475563

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
75.0075.0075.0075.0075.0075.0075.0075.0075.00
4.024.364.504.524.894.804.634.624.79
7.507.347.307.797.717.767.707.687.81
Government0.000.000.000.000.000.000.000.000.00
13.4813.3013.1912.6912.4112.4512.6612.7012.41

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-02
General Updates

2026-09-02 - GlaxoSmithKline PharmCorrigendum to the Notice of Postal Ballot dated August 3, 2026 aceuticals Limited has informed the Exchange about General UpdatesCorrigendum to the Notice of Postal Ballot dated August 3, 2026

2026-09-02
Shareholders meeting

2026-09-02 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot

2026-09-02
Copy of Newspaper Publication

2026-09-02 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-19
General Updates

2026-08-19 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about General Updates

2026-08-14
Copy of Newspaper Publication

2026-08-14 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-13
Shareholders meeting

2026-08-13 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot

2026-08-06
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-06 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Transcript

2026-08-06
Action(s) taken or orders passed

2026-08-06 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed

2026-08-05
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-05 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Link of Recording

News

Recent coverage and analyst commentary for GLAXO

Loading news…

🤖

AI Stock Analyst

Glaxosmithkline Pharmaceuticals Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login